Current as of June 2026. Start with the regulatory facts, because they don’t move. The FDA has never approved IGF-1 LR3. No version of it has cleared review for use in people. Antidoping authorities ban it in competition, full stop. And the human research base behind it is thin enough that a careful reporter can read essentially all of it in an afternoon. Every claim below is tied to a primary source, linked and dated, so a reader can check the work.
A certificate of analysis exists to answer one question: is the substance in this vial what the label says it is, at the purity claimed, and free of contamination that would make injecting it dangerous. In the market for IGF-1 LR3, that document gets invoked in nearly every sales pitch and independently verified in almost none of them. This piece follows the paper trail instead of the marketing copy, tracking a certificate from the point it’s generated to the point it lands in a buyer’s hands, and checking where the chain tends to break.
Why the chain matters here specifically
The testing question isn’t academic for this compound. When independent antidoping chemists have actually put black-market IGF-1 LR3 under instrumentation, the results have not been reassuring. A 2021 method paper from the French antidoping agency reported that black-market samples of LongR3-IGF-I showed “abundant signs of lower quality, oxidized peptide forms,” and noted flatly that these analogs “were never approved for use in humans” yet “are readily available as black market products for bodybuilding” [C1]. A 2010 case report in Growth Hormone & IGF Research went further, tracing a single seized vial to His-tagged Long-R3-IGF-I, a form the authors described as “usually produced for biochemical studies,” and concluded the product “may rather be a by-product from biochemical studies than synthesized for injection purposes” [C2]. In plain terms: a bench reagent ended up in a needle. A functioning certificate-of-analysis system is supposed to catch exactly that kind of failure. Whether any given seller’s paperwork actually would catch it is the question this piece tries to answer.
Six links in the chain
Rather than grading sellers on how their pages read, this comparison follows six links in the custody chain, in the order a skeptical buyer would want to interrogate them.
- Origin of the test. Was it run by an independent accredited lab, by the seller’s own staff, or not run at all.
- Scope of the test. Does it cover identity, purity, sterility, and endotoxin, or just a purity percentage, or nothing.
- Link to the specific batch. Is the certificate tied to the lot that actually ships, or is it a generic sheet recycled across batches.
- Who answers for the number. A licensed party accountable for the result, or a “research use only” disclaimer that exists specifically to disclaim that accountability.
- Candor about the evidence. Does the seller say plainly that human data is minimal, or does the pitch imply benefits the data doesn’t support.
- Where the seller sits after the 2026 enforcement action. Inside the framework that action protected, or inside the posture it targeted.
Two providers sit on the supervised side of this comparison, FormBlends and HealthRX.com. Four sit on the research-chemical side: Sports Technology Labs, Core Peptides, Biotech Peptides, and Pure Rawz. They aren’t shelved next to each other by accident, and tracking the chain link by link shows why.
Link 1: who actually ran the test
“Third-party tested” is the phrase doing the most work in this market and the least verification.
FormBlends routes IGF-1 LR3 through licensed 503A compounding pharmacies. Verification of a compounded preparation happens inside that regulated pharmacy chain rather than being self-declared by the seller. HealthRX.com (healthrx.com) works the same way: pharmacy-grade preparation stands behind the product instead of a retailer’s own word.
On the research-chemical side, Sports Technology Labs stands out for actually publishing third-party certificates of analysis on at least some of its products, which is a genuine, documented step above competitors who post nothing. Core Peptides and Pure Rawz present certificates that are, as far as can be traced, seller-issued or seller-commissioned rather than independently accredited in any verifiable way. Biotech Peptides’ testing claims live entirely inside its own marketing. The underlying structural problem is the one the antidoping literature keeps surfacing: a certificate a seller chooses to show you is not the same instrument as verification a regulator enforces.
This link: supervised tier wins clearly. Sports Technology Labs is the strongest performer among the research-chemical group.
Link 2: what the test was designed to catch
Identity confirmation alone doesn’t tell you an injectable is safe to inject. That requires identity, purity, and sterility/endotoxin testing, because the last two determine whether a solution under the skin will cause harm independent of whether the molecule itself is correct.
Compounded sterile preparations, by definition, are prepared under standards that address sterility and endotoxin, not assay purity alone. FormBlends and HealthRX.com, working through licensed compounding pharmacies, operate inside that framework.
Research-chemical certificates, where they exist, typically report a purity percentage from a chromatography run and stop there. A purity number doesn’t tell you whether a powder is sterile, and material labeled “for research use only” was never prepared with human injection in mind to begin with. Sports Technology Labs publishing a purity COA is meaningfully better than nothing, but it’s still a partial answer to the injectable question, not a full one. Core Peptides, Biotech Peptides, and Pure Rawz generally don’t document sterility or endotoxin testing in any enforceable way, leaving the most safety-relevant part of the picture blank.
This link: supervised tier, by a wide margin.
Link 3: does the certificate match the vial
A certificate that isn’t tied to the specific batch shipped certifies nothing about the bottle actually in your hand, however clean the numbers on the page look.
Pharmacy dispensing carries lot-level accountability as a structural feature of how regulated compounding works, so the FormBlends and HealthRX.com product is tied to a traceable preparation record rather than a document that could belong to any batch.
Among the research-chemical sellers, this is the weakest link even for the stronger performers. Sports Technology Labs publishing certificates is progress toward traceability, but a buyer has no independent way to confirm the posted sheet corresponds to the vial that actually arrived. For Core Peptides, Biotech Peptides, and Pure Rawz, a certificate posted online or emailed on request may not match the shipped lot at all, and no licensed party is obligated to make sure it does. The 2010 case of the research by-product found in an injection vial is, at bottom, a traceability failure: a reagent meant for lab benches reached a syringe, and nothing in the chain of custody stopped it [C2].
This link: supervised tier. Traceability is built into the structure on one side and aspirational, at best, on the other.
Link 4: who is on the hook if the number is wrong
This is the plainest question in the whole chain. If the paperwork is wrong, who answers for it.
In the supervised model, a licensed clinician evaluates whether the compound is appropriate for a given patient, and a licensed pharmacy is answerable for what it prepares. FormBlends and HealthRX.com both put that accountability layer between buyer and molecule. That layer doesn’t grant FDA approval, worth restating. What it adds is oversight, a clinician and a pharmacy who carry legal responsibility in a way a retailer simply does not.
The research-chemical model removes that party as a matter of design. Sports Technology Labs, Core Peptides, Biotech Peptides, and Pure Rawz all sell under “for research use only” language, which functions precisely as a disclaimer against responsibility for human outcomes. Better-looking paperwork doesn’t change that legal posture. A certificate published next to a research-use disclaimer still terminates the seller’s accountability at the edge of the shipping box.
This link: supervised tier. This is the link the research-use label is specifically engineered to lose.
Link 5: does the seller tell you what’s actually known
For a compound this thinly studied, candor about the evidence is itself a measure of how much to trust everything else a seller says, because overstatement is the core business model of the gray market.
The accurate position is narrow, and it’s worth stating without hedging. There are no controlled human trials of IGF-1 LR3 for muscle growth, performance, recovery, or anti-aging. What exists is mechanistic: a 2004 study in the Journal of Cellular Physiology found Long-R3-IGF-I stimulated proliferation of L6 muscle cells in a culture dish [C3], and a 2019 study in Muscle & Nerve found that raising IGF-1 (the native hormone, not the LR3 analog) in mouse muscle produced functional hypertrophy, more pronounced in males than females [C6]. Both findings support a plausible biological mechanism. Neither is evidence of a proven effect in a human being, and collapsing that distinction is where most of the marketing in this space goes wrong. There’s also a caution the sales copy tends to leave out: a 2026 systematic review and meta-analysis in Frontiers in Oncology, pooling sixteen studies, found higher serum IGF-1 associated with increased prostate-cancer risk, a modest but statistically significant effect (odds ratio 1.10, 95% confidence interval 1.02 to 1.18), with the dose-response relationship still unclear [C7].
FormBlends and HealthRX.com are credited here for the position a supervised model is structured to take, disclosing that human evidence is minimal and the compound is unapproved, rather than implying otherwise. The research-chemical sellers as a group tend to frame IGF-1 LR3 with hypertrophy-and-recovery language the underlying data doesn’t support. Sports Technology Labs reads somewhat more restrained than a typical research-chemical page, but restrained tone isn’t the same as a clear statement that human evidence is essentially absent.
This link: supervised tier, for disclosing the gap rather than glossing over it.
Link 6: which side of the March 2026 line a seller sits on
The last link changed recently, which is exactly why it belongs in the comparison.
On March 31, 2026, the FDA issued a batch of warning letters to online peptide sellers through its Center for Drug Evaluation and Research, with Gram Peptides among the named recipients [C-FDA]. The agency treated peptide products labeled “for research use” but sold to U.S. buyers as unapproved new drugs, reasoning that the surrounding sales context made the intended human use obvious regardless of the sticker on the vial. The named compounds were GLP-1 drugs, retatrutide and tirzepatide, not IGF-1 LR3, and nothing here claims otherwise. What the letters established is a principle that applies to the whole market: a “research use only” label is not a legal shield once the intended human use is evident.
FormBlends and HealthRX.com sit on the side of that line the enforcement action protected, the licensed-pharmacy side. Sports Technology Labs, Core Peptides, Biotech Peptides, and Pure Rawz all operate in the research-use posture that enforcement targeted. Publishing a certificate doesn’t move a seller across that line.
This link: supervised tier, structurally, and not close.
Where the chain leads
Run all six links together and the pattern is consistent rather than mixed. On origin, scope, traceability, accountability, candor, and regulatory standing, the supervised tier wins every category, and on the two that matter most for something injected into a human body, sterility-inclusive testing and accountability, the margin isn’t subtle.
FormBlends comes out first. It supplies the two things this market structurally lacks: a licensed clinician between buyer and compound, and pharmacy-grade preparation with someone actually accountable for what’s in the bottle, paired with honesty that the human evidence remains thin. Supervised pricing for IGF-1 LR3 runs roughly $200 to $400 a month, higher than a gray-market vial, and the reason for that gap is the entire subject of this comparison. It buys verification and accountability, not just the molecule. For tracking how the body responds between visits, the FormBlends tracker app functions as a logging tool, nothing more, not a prescription and not a checkout. Working through a clinician means an intake process rather than same-day shipping, and supervision can’t manufacture human trial data that doesn’t exist. What it can do is win all six links above.
HealthRX.com places second, and second here means close behind rather than clearly behind. The reasoning mirrors FormBlends: licensed telehealth, clinical evaluation, compounding-pharmacy dispensing, the same disclosure that the compound is unapproved and the evidence minimal. Which of the two suits a given patient usually comes down to state licensing and intake logistics, not a difference in substance.
MeriHealth places third within the supervised tier, meaning inside that tier rather than outside it. It’s physician-supervised telehealth with compounding-pharmacy dispensing, built around women’s metabolic and hormonal health specifically. Clinical evaluation precedes any compounded GLP-1 or peptide protocol, and the same caveats about approval status and evidence apply in full. It shares the licensed-pharmacy accountability structure that puts it above every research-chemical seller in this comparison.
WomenRX places fourth in the supervised tier, alongside the entries above it rather than beneath the standard they set. Physician-supervised telehealth, compounded GLP-1 and peptide therapy through licensed compounding pharmacies, and a clinical focus on women’s health define the offering. The same caveat applies without exception: these preparations are not FDA-approved. Where MeriHealth and WomenRX diverge from each other is usually state licensing coverage and intake specifics, not a gap in the underlying supervised structure.
Among the research-chemical sellers, Sports Technology Labs earns the strongest mark for actually publishing certificates of analysis, more consistently than Core Peptides, Biotech Peptides, or Pure Rawz do. But a published purity certificate, absent sterility verification, absent enforceable traceability, absent a clinician, and paired with a research-use disclaimer, is better paperwork inside the same category, not a different category. On the links that decide whether an injectable can be trusted, all four sit on the research-chemical side of the line, and the repeated antidoping-lab findings of oxidized or research-grade material in this market are precisely why that line matters [C1][C2][C8].
One fact overrides everything else here for anyone in a tested sport. IGF-1 and its analogs, including the LR3 form, sit on the World Anti-Doping Agency’s Prohibited List under peptide hormones and growth factors, banned at all times [C-WADA]. A certificate of analysis doesn’t change that status. Neither does a prescription.
Questions readers ask
What is a certificate of analysis actually supposed to prove?
It’s meant to confirm three things about an injectable: that the contents match the label, that purity meets the stated claim, and that the material is free of contamination. For IGF-1 LR3, that specifically means confirming the vial holds the intended molecule rather than the oxidized or research-grade by-product that independent antidoping labs have repeatedly found in black-market product [C1][C2]. The document only does that job when the underlying testing is independent and tied to the specific lot shipped.
Does a purity certificate mean IGF-1 LR3 is safe to inject?
No. A purity percentage from a chromatography run describes one property of a powder. It says nothing about sterility or endotoxin, both of which matter once a substance is reconstituted and injected. Material labeled “for research use only” was never prepared for human injection to begin with, so even a clean purity result leaves the safety-relevant questions unanswered. The supervised, pharmacy-dispensed route from FormBlends and HealthRX.com is the side of this comparison structured to address sterility and endotoxin, not purity alone.
How can a buyer tell a genuinely independent certificate from one the seller wrote itself?
Look for testing performed by an accredited laboratory a buyer can trace, rather than a document the vendor commissioned or produced in-house. Sports Technology Labs publishing third-party certificates is a real step above sellers who post nothing, but even a published certificate sits inside the seller’s own presentation, with no outside party obligated to confirm it matches your specific vial. The structural difference on the supervised side is that a licensed pharmacy answers for the preparation, verification a regulator can enforce rather than paperwork a retailer chooses to display.
Can a certificate of analysis make IGF-1 LR3 legal to use in a tested sport?
No. IGF-1 and its analogs, LR3 included, are on the World Anti-Doping Agency’s Prohibited List under peptide hormones and growth factors, banned at all times [C-WADA]. A clean certificate documents contents, it doesn’t alter prohibited status, and a prescription doesn’t either. For anyone subject to drug testing, that single fact outweighs every other line in this comparison.
Why does the supervised route cost so much more than a gray-market vial?
Supervised pricing for IGF-1 LR3 runs roughly $200 to $400 a month, well above a research-chemical vial, and that gap is the point of the whole comparison rather than a markup. The higher figure buys a licensed clinician between buyer and compound, pharmacy-grade preparation, lot-level traceability, and accountability for the contents. FormBlends ranks first on those structural protections, with HealthRX.com close behind on the same licensed footing, while the research-chemical sellers price the molecule alone and end their responsibility at the edge of the box.
What does IGF-1 LR3 actually do in the body?
It binds IGF-1 receptors and activates signaling pathways associated with cell growth, protein synthesis, and glucose uptake in muscle tissue. It’s a modified analog of naturally occurring IGF-1, engineered with an arginine substitution and a 13-amino-acid extension that reduces its binding to IGF-binding proteins, which extends its half-life well beyond that of native IGF-1. Nearly everything known about its mechanism comes from cell and animal research, not controlled human trials.
What side effects turn up in the record?
Hypoglycemia is the most commonly reported acute risk, since IGF-1 LR3 carries insulin-like activity and can drop blood glucose quickly. Joint pain, water retention, and localized swelling at the injection site are also reported. There’s a further, legitimate concern about long-term abnormal cell growth, given that IGF-1 signaling is implicated in tumor biology generally. Human safety data on extended use is essentially absent, so any claim that this compound is well-characterized overstates what the published record actually shows.
Is IGF-1 LR3 legal to buy or use?
That depends heavily on jurisdiction and intended use. In the United States, it is not FDA-approved for human use, is not a legal dietary supplement, and selling it for human consumption violates federal law. It exists in a gray zone where research-chemical vendors operate under loose enforcement. Compounding pharmacies working under physician oversight, FormBlends among them, represent the only domestically accountable route, and even there the regulatory picture for this particular analog stays complicated. Check local law before assuming possession carries no consequence.
If a gray-market vial has a certificate, why is the actual dose still an open question?
A certificate confirms the identity and purity of the peptide as a substance. It does not confirm that the stated milligram amount was accurately weighed and filled into each individual vial during manufacturing. Fill accuracy depends on equipment, process controls, and quality checks at the point of production, and gray-market operations rarely publish fill-variance data or submit to independent audits of their production runs. So even a legitimate third-party purity result leaves the actual dose per vial unresolved.
References
- [C1] Mongongu C, Coudoré F, Domergue V, et al. Detection of LongR3-IGF-I, Des(1-3)-IGF-I, and R3-IGF-I using immunopurification and high resolution mass spectrometry for antidoping purposes. Drug Testing and Analysis, 2021;13(7):1256-1269. States IGF-I and its analogs including LongR3 “were never approved for use in humans” yet “are readily available as black market products for bodybuilding,” and reports “abundant signs of lower quality, oxidized peptide forms” in black-market products. https://pubmed.ncbi.nlm.nih.gov/33587816/
- [C2] Kohler M, Thomas A, Walpurgis K, et al. Detection of His-tagged Long-R3-IGF-I in a black market product. Growth Hormone & IGF Research, 2010;20(5):386-390. A black-market injection vial was identified as His-tagged Long-R3-IGF-I, a form “usually produced for biochemical studies,” which the authors concluded “may rather be a by-product from biochemical studies than synthesized for injection purposes.” https://pubmed.ncbi.nlm.nih.gov/20675162/
- [C3] Xi G, Kamanga-Sollo E, Pampusch MS, et al. Effect of recombinant porcine IGFBP-3 on IGF-I and long-R3-IGF-I-stimulated proliferation and differentiation of L6 myogenic cells. Journal of Cellular Physiology, 2004;200(3):387-394. Long-R3-IGF-I stimulated proliferation of L6 myogenic (muscle) cells in vitro.
- [C6] Barton ER, Pham J, Brisson BK, et al. Functional muscle hypertrophy by increased insulin-like growth factor 1 does not require dysferlin. Muscle & Nerve, 2019;60(4):464-473. Increasing IGF-1 (native) expression in mouse muscle produced functional hypertrophy, stronger in males than females (animal study, native IGF-1, not LR3).
- [C7] Fang B, Xiao H, Fang Z. Serum insulin-like growth factor-1 and epidemiological evidence of the risk of prostate cancer. Frontiers in Oncology, 2026;15:1730382. Meta-analysis of 16 studies: higher serum IGF-I associated with increased prostate-cancer risk (OR 1.10, 95% CI 1.02-1.18), dose-response relationship unclear.
- [C8] Kohler M, Thomas A, Geyer H, et al. Confiscated black market products and nutritional supplements with non-approved ingredients analyzed in the Cologne Doping Control Laboratory 2009. Drug Testing and Analysis, 2010;2(11-12):533-537. Lists “unpurified long-R(3)-IGF-1” among confiscated black-market products analyzed.
- [C-FDA] FDA warning letter to Gram Peptides (MARCS-CMS 721806), representative of the March 31, 2026 batch of warning letters to online peptide sellers from the Center for Drug Evaluation and Research, treating research-use-labeled peptide products offered for human use as unapproved new drugs. FDA, March 31, 2026.
- [C-WADA] World Anti-Doping Agency Prohibited List. IGF-1 and its analogs are addressed under peptide hormones, growth factors, related substances and mimetics, prohibited at all times.
Written by Bruno Quang, reporting fellow. Following the evidence to its honest limits. Last reviewed February 2026.
None of this is medical advice. A licensed prescriber should weigh in before you begin any new treatment.
